The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, ...

Mandy Lauw, MD, PhD, recently honored with first-ever Young EHA Award, advocates for bigger roles for early-career clinicians ...

The upgrade followed Incyte Corp.’s (NASDAQ:INCY) third quarter earnings results last week, where it quadrupled its net ...

PureTech to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at ASH Annual Meeting ...

The abstract, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be featured in Poster Session B on January 9. It will also be published in the ...

Research presented at ESMO Congress 2025 demonstrates that adolescents and young adults are aware of skin cancer, but still do not consistently practice preventive behaviors. Research demonstrates ...

Recordati Rare Diseases Inc. today announced the presentation of new data related to its growing portfolio of treatments for rare hematologic disorders at the 67th American Society of Hematology (ASH) ...

Through this deepened collaboration, CTI is accredited in Medidata eCOA to further improve data collection capabilities, enhancing the clinical trial experience for patients by enabling the collection ...

Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY ...